Charles Turner, MD
Internal Medicine · Glasgow, KYNPI 1841487659
Payments from drug & device makers
Across 101 payments — averaging $13.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$418
- AbbVie$140
- Amgen$128
- Pfizer$84
- GSK$70
- Johnson & Johnson$70
- plus $440 from 18 others
What the payments were for
- Food & beverage$1,350100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 36 | $418 |
| AbbVie(2 entities) | 10 | $140 |
| Amgen | 8 | $128 |
| Pfizer | 5 | $84 |
| GSK | 5 | $70 |
| Johnson & Johnson | 6 | $70 |
| AstraZeneca | 5 | $67 |
| Merck | 4 | $49 |
| Boehringer Ingelheim | 2 | $34 |
| Insulet Corporation | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Bayer | 2 | $27 |
| Esperion Therapeutics, Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Novartis | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $11 |
How this compares
$1,350 in reported general payments places this provider in the 70th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $205,519 |
| EliquisApixaban | 200 | $191,481 |
| TrulicityDulaglutide | 92 | $121,549 |
| JardianceEmpagliflozin | 76 | $80,669 |
| JanuviaSitagliptin Phosphate | 86 | $67,044 |
| MounjaroTirzepatide | 49 | $63,041 |
| FarxigaDapagliflozin Propanediol | 51 | $53,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $47,165 |
| MyrbetriqMirabegron | 72 | $41,094 |
| XareltoRivaroxaban | 37 | $36,817 |
| TradjentaLinagliptin | 29 | $36,043 |
| RybelsusSemaglutide | 23 | $34,278 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $28,988 |
| VascepaIcosapent Ethyl | 56 | $27,897 |
| LinzessLinaclotide | 24 | $22,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $418 | $239,797181 claims |
| PfizerEliquis, Premarin | $84 | $196,465211 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $21 | $184,591141 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat | $34 | $140,431135 claims |
| MerckJanuvia, Janumet Xr | $49 | $76,35897 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $70 | $67,872110 claims |
| AstraZenecaFarxiga, Symbicort | $67 | $63,12282 claims |
| Johnson & JohnsonXarelto, Invokana | $70 | $51,98753 claims |
| AbbVieLinzess, Synthroid | $140 | $31,181154 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $22 | $21,96932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Glasgow
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.